FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2966720565> ?p ?o ?g. }

• W2966720565 abstract "e13508 Background: Due to chronic hypoxia cancer cells are growing in a more acidic environment compared to physiological tissue. Using this differentiation a new therapy method has been developed for targeted chemotherapy. Recent preclinical in vitro and in vivo data have shown direct pH-sensitive anti-tumor activity by pore formation and apoptosis when synergistically acting combinations of diflunisal, paraaminosalicylic acid (PAS) and aspirin were applied. Therefore, a pilot study was performed to evaluate its clinical relevance. Methods: A total of 30 patients (n=30) with advanced solid tumors and the lack of standard treatments were treated with a protocol consisting of 3-5 weeks with 2 daily i.v. infusions of diflunisal and aspirin for 4 days per week after they had signed an informed consent form. Response evaluation was assessed by PET/CT differentiating in metabolic and metric (RECIST) response. Results: Out of 30 patients treated 4 patients suffered from colorectal cancer, 11 from breast cancer, 2 from ovarian cancer, 2 from lung cancer, 2 from gastric cancer, 2 from glioblastoma, 1 from CUP, 1 from hemangioendothelioma, 1 from pleuramesothelioma, 1 from non-Hodgkin lymphoma, 1 from pancreatic cancer, 1 from choledochus cancer, 1 from prostate cancer, respectively. Side effects related to the therapy have been fatigue (6,7%), nausea (13,3%), tinnitus (10%), hypertension (6,7%), dyspnea (3,3%) and burning sensation in tumor areas (3,3%). Out of 30 patients treated, until today 14 were evaluable for metric response, 12 for metabolic and 13 for tumor marker response assessment. For tumor marker follow up 2 patientis (6,7 %) had a CR, 6 (20 %) a PR, 4 (13,3 %) a SD of > 3 month and 1 (3,3 %) a PD. For metric follow up 0 patients (0 %) had a CR, 6 (20 %) a PR, 5 (16,7 %) a SD of > 3 month and 3 (10 %) a PD. For metabolic follow up 1 patients (3,3 %) had a CR, 3 (10 %) a PR, 5 (16,7 %) a SD of > 3 month and 3 (10 %) a PD. Conclusions: This pilot study confirms a direct pH-sensitive synergistic anti-tumor activity of intravenous salicylic acids in patients with advanced solid tumors. Therefore, a further evaluation in a controlled clinical phase II study will be performed." @default.
• W2966720565 created "2019-08-13" @default.
• W2966720565 creator A5018500838 @default.
• W2966720565 creator A5037655243 @default.
• W2966720565 creator A5058952845 @default.
• W2966720565 creator A5064715555 @default.
• W2966720565 creator A5070739174 @default.
• W2966720565 creator A5046121187 @default.
• W2966720565 date "2012-05-20" @default.
• W2966720565 modified "2023-09-25" @default.
• W2966720565 title "Pilot study on antitumor efficacy of intravenously applied synergistic combinations of salicylic acids in patients with advanced solid tumors." @default.
• W2966720565 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.e13508" @default.
• W2966720565 hasPublicationYear "2012" @default.
• W2966720565 type Work @default.
• W2966720565 sameAs 2966720565 @default.
• W2966720565 citedByCount "0" @default.
• W2966720565 crossrefType "journal-article" @default.
• W2966720565 hasAuthorship W2966720565A5018500838 @default.
• W2966720565 hasAuthorship W2966720565A5037655243 @default.
• W2966720565 hasAuthorship W2966720565A5046121187 @default.
• W2966720565 hasAuthorship W2966720565A5058952845 @default.
• W2966720565 hasAuthorship W2966720565A5064715555 @default.
• W2966720565 hasAuthorship W2966720565A5070739174 @default.
• W2966720565 hasConcept C121608353 @default.
• W2966720565 hasConcept C126322002 @default.
• W2966720565 hasConcept C185592680 @default.
• W2966720565 hasConcept C2778221352 @default.
• W2966720565 hasConcept C2993640289 @default.
• W2966720565 hasConcept C502942594 @default.
• W2966720565 hasConcept C55493867 @default.
• W2966720565 hasConcept C71924100 @default.
• W2966720565 hasConcept C98274493 @default.
• W2966720565 hasConceptScore W2966720565C121608353 @default.
• W2966720565 hasConceptScore W2966720565C126322002 @default.
• W2966720565 hasConceptScore W2966720565C185592680 @default.
• W2966720565 hasConceptScore W2966720565C2778221352 @default.
• W2966720565 hasConceptScore W2966720565C2993640289 @default.
• W2966720565 hasConceptScore W2966720565C502942594 @default.
• W2966720565 hasConceptScore W2966720565C55493867 @default.
• W2966720565 hasConceptScore W2966720565C71924100 @default.
• W2966720565 hasConceptScore W2966720565C98274493 @default.
• W2966720565 hasLocation W29667205651 @default.
• W2966720565 hasOpenAccess W2966720565 @default.
• W2966720565 hasPrimaryLocation W29667205651 @default.
• W2966720565 hasRelatedWork W1541058529 @default.
• W2966720565 hasRelatedWork W1566522679 @default.
• W2966720565 hasRelatedWork W1970567191 @default.
• W2966720565 hasRelatedWork W2009776989 @default.
• W2966720565 hasRelatedWork W2023657097 @default.
• W2966720565 hasRelatedWork W2034132202 @default.
• W2966720565 hasRelatedWork W2136923586 @default.
• W2966720565 hasRelatedWork W2139647458 @default.
• W2966720565 hasRelatedWork W2163564352 @default.
• W2966720565 hasRelatedWork W2374043838 @default.
• W2966720565 hasRelatedWork W2389078705 @default.
• W2966720565 hasRelatedWork W2396325839 @default.
• W2966720565 hasRelatedWork W2399031549 @default.
• W2966720565 hasRelatedWork W2401798259 @default.
• W2966720565 hasRelatedWork W2469538150 @default.
• W2966720565 hasRelatedWork W2499752707 @default.
• W2966720565 hasRelatedWork W2998380376 @default.
• W2966720565 hasRelatedWork W3015662225 @default.
• W2966720565 hasRelatedWork W3036706037 @default.
• W2966720565 hasRelatedWork W124514418 @default.
• W2966720565 isParatext "false" @default.
• W2966720565 isRetracted "false" @default.
• W2966720565 magId "2966720565" @default.
• W2966720565 workType "article" @default.